Oric Pharmaceuticals (ORIC) Gets a Buy Rating from Robert W. Baird
In a report issued on May 7, Colleen M. Kusy from Robert W. Baird maintained a Buy rating on Oric Pharmaceuticals (ORIC), with a price target of $45.00. The company’s shares closed last Monday at $22.44.
According to TipRanks.com, Kusy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -9.4% and a 18.2% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Apellis Pharmaceuticals, and Karyopharm Therapeutics.
Currently, the analyst consensus on Oric Pharmaceuticals is a Strong Buy with an average price target of $50.33, which is a 108.7% upside from current levels. In a report issued on May 6, Oppenheimer also assigned a Buy rating to the stock with a $52.00 price target.
See today’s analyst top recommended stocks >>
Based on Oric Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $28.26 million. In comparison, last year the company had a GAAP net loss of $8.87 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.